HUE069338T2 - (1R,3S)-3-((5-ciano-4-fenil-tiazol-2-il)karbamoil)ciklopentán-1-karbonsav légúti betegségek kezelésében történõ alkalmazásra - Google Patents

(1R,3S)-3-((5-ciano-4-fenil-tiazol-2-il)karbamoil)ciklopentán-1-karbonsav légúti betegségek kezelésében történõ alkalmazásra

Info

Publication number
HUE069338T2
HUE069338T2 HUE21765908A HUE21765908A HUE069338T2 HU E069338 T2 HUE069338 T2 HU E069338T2 HU E21765908 A HUE21765908 A HU E21765908A HU E21765908 A HUE21765908 A HU E21765908A HU E069338 T2 HUE069338 T2 HU E069338T2
Authority
HU
Hungary
Prior art keywords
phenylthiazol
cyclopentane
carbamoyl
cyano
treatment
Prior art date
Application number
HUE21765908A
Other languages
English (en)
Hungarian (hu)
Inventor
Palomino Laria Julio Castro-
Gomez Juan Camacho
Laria Nahomi Castro-Palomino
Alvarez Alina Ariosa
Original Assignee
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma Sl filed Critical Palobiofarma Sl
Publication of HUE069338T2 publication Critical patent/HUE069338T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HUE21765908A 2020-08-21 2021-08-20 (1R,3S)-3-((5-ciano-4-fenil-tiazol-2-il)karbamoil)ciklopentán-1-karbonsav légúti betegségek kezelésében történõ alkalmazásra HUE069338T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (1)

Publication Number Publication Date
HUE069338T2 true HUE069338T2 (hu) 2025-02-28

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21765908A HUE069338T2 (hu) 2020-08-21 2021-08-20 (1R,3S)-3-((5-ciano-4-fenil-tiazol-2-il)karbamoil)ciklopentán-1-karbonsav légúti betegségek kezelésében történõ alkalmazásra

Country Status (20)

Country Link
US (1) US20230321053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3957308A1 (cg-RX-API-DMAC7.html)
JP (1) JP7794807B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230054444A (cg-RX-API-DMAC7.html)
CN (1) CN115942933A (cg-RX-API-DMAC7.html)
AU (1) AU2021327728B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002778A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190081A1 (cg-RX-API-DMAC7.html)
DK (1) DK4199922T3 (cg-RX-API-DMAC7.html)
ES (1) ES3001104T3 (cg-RX-API-DMAC7.html)
FI (1) FI4199922T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069338T2 (cg-RX-API-DMAC7.html)
LT (1) LT4199922T (cg-RX-API-DMAC7.html)
MX (1) MX2023002156A (cg-RX-API-DMAC7.html)
PL (1) PL4199922T3 (cg-RX-API-DMAC7.html)
PT (1) PT4199922T (cg-RX-API-DMAC7.html)
RS (1) RS66263B1 (cg-RX-API-DMAC7.html)
SI (1) SI4199922T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022038261A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001881A2 (en) * 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2331220B1 (es) 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
AU2015315628A1 (en) * 2014-09-08 2017-04-20 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska

Also Published As

Publication number Publication date
JP2023538419A (ja) 2023-09-07
AU2021327728B2 (en) 2026-06-11
PL4199922T3 (pl) 2025-02-10
WO2022038261A1 (en) 2022-02-24
DK4199922T3 (da) 2024-11-25
CA3190081A1 (en) 2022-02-24
KR20230054444A (ko) 2023-04-24
RS66263B1 (sr) 2024-12-31
EP3957308A1 (en) 2022-02-23
BR112023002778A2 (pt) 2023-03-14
HRP20241621T1 (hr) 2025-01-31
CN115942933A (zh) 2023-04-07
SI4199922T1 (sl) 2025-03-31
US20230321053A1 (en) 2023-10-12
PT4199922T (pt) 2024-12-18
AU2021327728A1 (en) 2023-03-09
LT4199922T (lt) 2025-01-10
MX2023002156A (es) 2023-03-01
EP4199922A1 (en) 2023-06-28
EP4199922B1 (en) 2024-09-25
JP7794807B2 (ja) 2026-01-06
ES3001104T3 (es) 2025-03-04
FI4199922T3 (fi) 2024-12-05

Similar Documents

Publication Publication Date Title
TW202619727A (zh) 使用jak抑制劑治療化膿性汗腺炎
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2020132661A3 (en) Inhibitors of fibroblast activation protein
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
NZ591873A (en) Co-crystals of tramadol and nsaids
WO2008101907A3 (en) N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
SI4199922T1 (sl) (1r,3s)-3-((5-ciano-4-feniltiazol-2-il)karbamoil)ciklopentan-1-karboksilna kislina za uporabo pri zdravljenju bolezni dihal
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EP4006144A4 (en) THERAPEUTIC MEDICINE FOR FIBROSIS, INFLAMMATION AND/OR AGE-RELATED DISEASES
AU2022407131B2 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
IL313669A (en) New analogs of valproic acid and methods of medical treatment with their help
CR20210043A (es) Forma de dosificación farmacèutica administrable por vía oral con liberación modificada
CA3264923A1 (en) COMPOSITION INTENDED FOR USE IN THE TREATMENT OF FABRY'S DISEASE
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2020084113A8 (en) Sildenafil for use in the treatment of osteoarthritis
WO2016049580A3 (en) Inhibitors of nf kappa-b activity for treatment of diseases and disorders
HK40117956A (en) Novel analogs of valproic acid and methods of medical treatment using the same
HK40089625A (en) Treatment of respiratory diseases with amino acid compounds
CA3303563A1 (en) Stable glp-1 analogs for the treatment of human disease and disorders
AU2024220869A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis
CA3282958A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis